Jinling Pharmaceuticals: Holding Subsidiary Obtains Approval for Potassium Sulfate Listing.

Jinling Pharmaceutical announced that its holding subsidiary, Chizhou Dongsheng Pharmaceutical Co., Ltd., recently received the "Chemical Raw Material Drug Market Application Approval Notice" issued by the National Drug Administration, approving the registration of potassium sulfate. Potassium sulfate is one of the raw materials for the concentrated solution of magnesium sulfate, sodium sulfate, and potassium sulfate for oral administration, suitable for colon cleansing before any operation requiring a clean colon in adults. This approval indicates that the raw material drug meets the requirements for domestic drug registration and can be produced and sold in the domestic market, which is beneficial for enriching the company's raw material drug product line. However, as production and sales will take time, it will not have a significant impact on the company's current performance.